Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Disc Medicine, Inc. (IRON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $39.53 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $14.06, a 79.11% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $7.85.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $39.53, a 11.79% increase from fiscal 2024.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $35.36, a 33.23% increase from fiscal 2023.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $26.54, a 226.45% increase from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $8.13, a 63.25% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $39.53 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $35.36 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $35.55 10-Q · filed 2024-11-12 | ||||
| 2023-12-31 | $26.54 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $25.68 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $22.49 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | $14.06 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $8.13 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $7.21 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | $7.85 10-Q · filed 2023-08-11 | ||||
| 2022-03-31 | $7.85 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $4.98 10-K · filed 2023-03-31 | $8.13 10-K · filed 2022-03-10 | |||
| 2020-12-31 | $4.40 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |